The embryonic development of the pituitary gland involves a complex and highly spatio-temporally regulated network of integrating signalling molecules and transcription factors. Genetic mutations in any of these factors can lead to congenital hypopituitarism in association with a wide spectrum of craniofacial/midline defects ranging from incompatibility with life to holoprosencephaly (HPE) and cleft palate and septo-optic dysplasia (SOD). Increasing evidence supports a genotypic overlap with hypogonadotrophic hypogonadal disorders such as Kallmann syndrome, which is consistent with the known overlap in phenotypes between these disorders. This chapter reviews the cascade of events leading up to the successful development of the pituitary gland and to highlight key areas where genetic variations can occur thus leading to congenital hypopituitarism and associated defects.
The midline location of the pituitary gland and its close developmental associations with forebrain and eye development often results in the association of congenital hypopituitarism with highly heterogeneous midline defects ranging from incompatibility with life, to holoprosencephaly (HPE) and cleft palate and septo-optic dysplasia (SOD), which will be described later [3] .
The scope of this chapter is to provide a background on the development of the pituitary gland and the signalling molecules and transcription factors which drive this process. The genetic abnormalities which lead to associated defects such as HPE and SOD will also be described plus an update on the apparent overlap between these groups of disorders and Kallmann syndrome, defined as the combination of hypogonadotrophic hypogonadism (HH) and anosmia.
Pituitary Gland

Morphology
After the initial dorsal invagination of the primordium of the anterior pituitary lobe from the oral ectoderm (see below) to form Rathke's pouch (RP), a series of tightly regulated cellular proliferation and differentiation events eventually give rise to five highly differentiated cell types secreting a total of six hormones: (1) adrenocorticotrophic hormone (ACTH) from the corticotrophs, (2) thyrotrophin or thyroid stimulating hormone (TSH) from the thyrotrophs, (3) growth hormone (GH) from the somatotrophs, (4) prolactin from the lactotrophs, and (5) follicle-stimulating hormone (FSH) and luteinising hormone (LH) from the gonadotrophs [1] . The intermediate lobe, derived from the same invagination event, contains melanotrophs which secrete proopiomelanocortin (POMC), a major precursor protein to endorphins and melanocytestimulating hormone (MSH) [2] . Secreted hormones then interact with distinct targets throughout the body. The ventral diencephalon (VD) (primordial hypothalamus) component of the neural ectoderm evaginates ventrally to form the infundibulum (see below), which is destined to form the posterior pituitary and pituitary stalk, the latter structure acting as a physical connection between the pituitary gland and brain and containing the hypophyseal (hypothalamo-pituitary) portal system as well as neural connections between the hypothalamus and posterior pituitary [4] .
The posterior lobe is comprised of axonal projections of neurons which traverse the pituitary stalk and median eminence at the base of the hypothalamus. The neurons originate from hypothalamic magnocellular bodies termed the supraoptic, suprachiasmatic and paraventricular nuclei. The former two nuclei release arginine vasopressin whilst the paraventricular nuclei release oxytocin [4] . The median eminence contains a capillary bed into which parvocellular neurons, located in a variety of hypothalamic nuclei, secrete hypophysiotropic hormones which then reach the anterior and intermediate pituitary lobes via the hypophyseal portal system and stimulate the release of anterior/intermediate lobe hormones. Thus, it is the hypothalamus which acts as the central regulator of growth, reproduction and homeostasis via the pituitary gland [4] .
Timeline of Pituitary Organogenesis
Neurulation occurs at 3 weeks of gestation in humans and is the first known event of nervous system development [3] . This involves the thickening of the notochord to give rise to the neural plate (primordial central nervous system) from which the brain and spinal cord are derived. The anterior neural plate is the predecessor of the forebrain, optic nerves, hypothalamus and anterior and posterior pituitary lobes. The development of these latter structures has been well characterised in murine models [4] and is highly conserved across vertebrate species including humans. As such, the following paragraphs will outline murine pituitary organogenesis.
As embryogenesis proceeds, the growth and expansion of the brain causes the head of the embryo to bend anteriorly, displacing the heart ventrally and causing a depression between the heart and brain which is termed the stomodeum, or oral ectoderm. The thickening of the upper edge of the stomodeum at embryonic (E) day 8.5 marks the onset of pituitary organogenesis ( fig. 1 ). At E9.5, the thickened section of stomodeum invaginates to form the rudimentary RP. Twenty-four hours later, the infundibulum evaginates from the VD located within the neural ectoderm (which had thickened at E7.5) to come into contact with RP. This essential contact is maintained throughout pituitary organogenesis. At the same time, the connection between RP and the oral ectoderm is severed with the generation of a fully developed definitive pouch. From E12.5-E17.5 the progenitors of the five hormone-secreting cell types proliferate and terminally differentiate ventrally, while the dorsal portion of the pouch becomes the intermediate lobe, the size of which varies greatly between species and is largely absent in humans.
The first hormone-secreting cell types appear at the most ventral portion of RP at E11.5 after expressing the α-glycoprotein subunit (αGSU) [4] . These same cells express transcription factor islet-1 (Isl1) which corresponds to prospective thyrotrophs. These cells terminally differentiate at E12.5 after expressing thyroid-stimulating hormone subunit β (Tshβ), although these cells are short lived and disappear at birth. Dorsal to these intermediary thyrotrophs are corticotrophs which begin differentiating by E12.5. They express Pomc, as do the melanotropes from E14.5 in the intermediate lobe.
Around the same time definitive thyrotrophs are also detected in the anterior pituitary lobe [4] . At E15.5 somatotrophs and lactotrophs begin differentiating with the detection of growth hormone and prolactin, respectively. The former cell types then proliferate through the central and lateral aspects of the anterior lobe [4] . Lactotroph localisation is more restricted to the medial zone, adjacent to the intermediate lobe.
The gonadotrophs are the last anterior pituitary cell types to be detected with Fsh subunit β (Fshβ) detected at E16.5, followed by Lh subunit β (Lhb) one day later [4] .
Molecular Regulation of Pituitary Development
This section details the molecular regulation of murine pituitary development and how this fits with the timeline above, and is illustrated in figure 2 .
Factors Involved in the Early Formation of Rathke's Pouch
Bone Morphogenetic Protein 4 and the Sonic Hedgehog Pathway Bone morphogenetic protein 4 (BMP4) is the earliest signalling molecule known to be expressed in the prospective infundibulum at E8.5, as the stomodeum thickens to form the presumptive RP. As such, Bmp4 is required for the initiation of RP formation and its continued expression through to E14.5 suggests it is important for the maintenance of RP formation also. Complete deletion of Bmp4 usually results in early embryonic lethality [4] , although analyses of the few mice which survive to E10 show no signs of RP formation, or even a thickening of the stomodeum.
In humans, BMP4 is located on chromosome 14q22-q23 near the OTX2 gene [5, 6] . During embryogenesis BMP4 is expressed in the optic vesicle and optic cup, which is consistent with its known expression across species prior to lens formation. In the brain BMP4 is expressed in the diencephalic floor, consistent with its role in pituitary development and also the medial ganglionic eminence. BMP4 is also expressed in developing limbs [5, 6] . Various intragenic mutations including missense (heterozygous, compound heterozygous and homozygous), nonsense, chromosomal deletions and frameshift variations have been detected across multiple patients with various phenotypes including anophthalmia/microphthalmia, congenital glaucoma and sclerocornea (eyes), decreased brain white matter, lateral ventricular dilatation, hypoplastic corpus callosum, hydrocephaly, cleft lip and palate, developmental and growth delay (brain and craniofacial/midline structures) and postaxial polydactyly, syndactyly and brachydactyly (limbs) [5] . Interestingly, the literature is deficient on the state of the pituitary gland in most patients except for one case involving a chromosomal deletion of 14q22-q23 encompassing BMP4, OTX2 and SIX6 [6] . All three proteins are expressed in areas critical for pituitary development and as such it is not clear which of these proteins were causative of the pituitary phenotype. Thus further clarification of the pituitary phenotype in cases of isolated BMP4 mutations/deletions is required. BMP4, along with FGF8 (see below), appears to be involved in the spatiallyrestricted distribution of Sonic Hedgehog (SHH) expression within the oral ectoderm. In mice, genetic expression of Shh is extensive throughout the VD until E14.5 and oral ectoderm except for RP until E12.5. Shh is a member of the hedgehog family of morphogens which elicit different cellular responses and cell fates. It binds to the transmembrane protein Patched which subsequently dissociates from its co-receptor Smoothened thereby activating the GLI family of transcription factors, which are involved in activating or repressing target genes. Patched and the GLI transcription factors are expressed within RP (with the latter also being present in the VD) meaning that Shh can mediate pituitary development through these pathways [4] . Due to the severity of the mouse Shh-null phenotype which exhibits cyclopia and loss of brain midline structures, the pituitary phenotype cannot be assessed. However, mice which are transgenic for an inhibitor of the hedgehog family do develop RP due to the normal expression of Bmp4 and Fgf8, but it is severely hypoplastic. Humans with mutations in SHH exhibit holoprosencephaly (HPE), which is the failure of the brain to divide into its two hemispheres, often accompanied by craniofacial malformations and almost always developmental delay. Approximately 20 SHH mutations have been identified in HPE patients, with at least 8 mutants presenting dramatic impairment in the production of the active SHH N-terminal [7] . No SHH mutations have yet been discovered in patients with hypopituitarism either in isolation or in association with other defects. Similarly, human patients with mutations in GLI2 also present with HPE in conjunction with craniofacial/midline abnormalities such as a single central incisor, single nares, optic nerve hypoplasia, partial agenesis of the corpus callosum and pituitary gland dysfunction as well as postaxial polydactyly. There have been 17 GLI2 mutations identified in such patients with variable phenotypes (table 1), often with panhypopituitarism or isolated growth hormone deficiency. Recently, mutations in GLI2 have been associated with hypopituitarism in the absence of holoprosencephaly [8] . Loss-of-function studies show that the homozygous Gli2 knockout mouse is perinatal lethal with severe cartilage and bone developmental abnormalities [9] .
FGF8
Fibroblast growth factor 8 (Fgf8) is one member of the large fibroblast growth factor family (total of 23 members). It is expressed in the infundibulum by E9.5 and has been shown to regulate the expansion of RP through induction of Lhx3 and Lhx4 expression (see below) in the pouch [10] . In Fgf8 hypomorphic mice, the anterior pituitary gland is markedly hypoplastic and the posterior pituitary may be absent [10] . Midline defects including HPE were present in the mutant mice. The arginine vasopressin (AVP) and oxytocin neurons of the hypothalamus are also reduced in number; these data were consistent with the diabetes insipidus observed in an autosomal-recessive case of HPE due to a homozygous mutation in FGF8 [10] . Mutations in this gene were only recently ACC = Agenesis of the corpus callosum; ACTH = adenocorticotrophic hormone; CPHD = combined pituitary hormone deficit; EPP = ectopic posterior pituitary; FSH = follicle-stimulating hormone; GH = growth hormone; GHD = growth hormone deficiency; GnD = gonadotrophin deficiency; HH = hypogonadotrophic hypogonadism; HPE = holoprosencephaly; IGHD = isolated growth hormone deficiency; LH = luteinising hormone; PRL = prolactin; SOD = septo-optic dysplasia; TSH = thyroid-stimulating hormone.
described in patients with phenotypes associated with congenital hypopituitarism, including the above-mentioned patient with autosomal recessive HPE (table 1) [10] .
Lim Homeodomain Transcription Factors Lhx3 is expressed early during anterior pituitary development, initially with strong uniform expression within RP at E9.5 [11] as well as in the ventral hindbrain and spinal cord. Expression persists throughout the adult pituitary, suggesting a maintenance function in one or more of the anterior pituitary cell types [1] . Lhx3 -/-mice die shortly after birth and present with defects in the differentiation of all pituitary hormone secreting cell-types despite the initial formation of RP. Mutations in LHX3 have now been identified in a number of human pedigrees characterized by combined pituitary hormone deficiency and cervical abnormalities with or without restricted neck rotation; some patients also exhibit sensorineural hearing loss (table 1) [4] . Magnetic resonance imaging reveals a small or enlarged anterior pituitary with a structurally normal posterior pituitary. In some patients, a microadenoma may be observed.
Closely related to Lhx3 is Lhx4 which is also expressed throughout the invaginating RP at E9.5. Its expression, however, is transient and becomes restricted to the future anterior lobe by E12.5 and eventually downregulated at E15.5 [12] . Loss of Lhx4 does not prevent definitive pouch formation but results in the formation of a hypoplastic pituitary, containing each of the differentiated cell types albeit at lower numbers compared to wild-type mice (in contrast to Lhx3 mutants). Mice die shortly after birth. Patients with LHX4 mutations have variable phenotypes including GHD and variable TSH, gonadotrophin and ACTH deficiencies with a hypoplastic anterior pituitary, with or without an ectopic posterior pituitary (table 1) [1] .
Another family member, Lhx2, which is expressed in the VD, infundibulum and posterior pituitary, had been known to cause anophthalmia and malformation of the cerebral cortex when disrupted in mice. More recently, deletions in Lhx2 were demonstrated to disrupt the morphology and organisation of RP despite all endocrine cell lineages being present [3] . No mutations in humans with hypopituitarism have been detected although one heterozygous variant (p.P43A), predicted to be significant, was recently detected in a patient with anophthalmia, although the paternal carrier was phenotypically normal [13] .
HESX1
Homeobox embryonic stem cell 1 (HESX1) is a member of the paired-like homeobox gene family which encodes transcription factors that contain a DNA-binding homeodomain. It is a transcriptional repressor, expressed early in the anterior visceral endoderm and adjacent ectoderm in an area destined to become the ventral prosencephalon and forebrain. By E9.0, expression is restricted to the VD and presumptive RP [3] . Hesx1 appears to have a role in RP cellular proliferation and patterning, as its gradual downregulation is concomitant with a gradual increase in the expression of another pairedlike homebox gene, Prophet of Pit1 (PROP1 -see below) [14] . This down-regulation of Hesx1 is essential for pituitary development and expression ceases by E13.5 [3] . Initial activation of Hesx1 is dependent upon Lhx1 and Lhx3 via its 5Ј promoter region. 3Ј elements are essential for later expression in the developing pouch [4] .
In humans, HESX1 mutations may occur in association with isolated growth hormone deficiency (IGHD) or combined pituitary hormone deficiency (CPHD), frequently in association with septo-optic dysplasia (SOD) phenotypes characterized by the presence of optic nerve hypoplasia or midline abnormalities of the brain. These patients exhibit variable MRI abnormalities ranging from a structurally normal pituitary to a more severe radiological phenotype characterized by anterior pituitary hypoplasia, an undescended or ectopic posterior pituitary, optic nerve hypoplasia and agenesis of the corpus callosum [2] . Mutations in HESX1 can result in hypopituitarism without midline defects or optic nerve anomalies, as the pituitary is believed to be highly sensitive to Hesx1 dosage (table 1) [15] . SOX2 and SOX3 SOX2 and SOX3 are members of the SOX [SRY-related high mobility group (HMG) box] family of transcription factors and are early markers of progenitor cells; their expression is down-regulated as cells differentiate. Strong SOX2 expression is detected within RP in human embryos (4.5-9 weeks of development), which is maintained throughout anterior pituitary development as well as in the overlying diencephalon. However, there is no SOX2 expression in the infundibulum or posterior pituitary. Initially SOX2 mutations had been associated with bilateral anophthalmia, severe microphthalmia, learning difficulties, oesophageal atresia and genital abnormalities (table 1) . However, further phenotypic characterization has revealed the presence of anterior pituitary hypoplasia, hypogonadotrophic hypogonadism and variable GHD, often with accompanying phenotypes such as hippocampal abnormalities, corpus callosum agenesis, oesophageal atresia, hypothalamic hamartoma and sensorineural hearing loss [3] . Although in the majority of patients the MRI reveals a small anterior pituitary, in occasional cases, the pituitary is enlarged and remains so for years. The definitive Rathke's pouch comprises proliferative progenitors that will gradually relocate ventrally, away from the lumen as they differentiate. A proliferative zone containing progenitors is maintained in the embryo in a perilumenal area and was recently found to persist in the adult [4] . During pituitary development, SOX2 is expressed in the early ectoderm and maintained throughout the pouch. Its expression is downregulated as endocrine cell differentiation proceeds. Expression is maintained in the prospective progenitor proliferative zone, around the Rathke's pouch lumen, during embryogenesis but also in the mature gland [4] . It is also expressed in the VD.
Normal hypothalamo-pituitary development is critically dependent upon the dosage of SOX3; over-or underdosage can lead to hypopituitarism or infundibular hypoplasia. Sox3 null mutant mice have a variable phenotype showing poor growth, craniofacial defects, and variable endocrine deficits. In humans, SOX3 mutations are associated with variable phenotypes including either IGHD or panhypopituitarism.
There is variable developmental delay, and MRI usually reveals a small anterior pituitary, an ectopic/undescended posterior pituitary, and dysgenesis of the corpus callosum (table 1) [16] . Recently, a SOX3 variant that leads to a deletion within a polyalanine tract has been associated with hypopituitarism in a heterozygous female patient; the variant has been shown to be associated with a gain in function as opposed to the previously described polyalanine expansions which led to loss of function [16, 17] .
OTX2
Orthodentic homeobox 2 (Otx2) is a transcription factor whose role in hypothalamopituitary axial development remains largely unclear. Expression in mice is restricted to developing neural and sensory structures such as the brain, eyes, nose and ears. Recent elucidations show that Otx2 is expressed in the VD by E10.5 where it may affect Fgf8 and/or Bmp induction of RP formation [18] . Its expression at the same time in RP suggests an intrinsic role in RP development as well, which is consistent with its proposed ability to activate Hesx1 expression. By E12.5, Otx2 mRNA expression is undetectable in RP (however, it is still detectable in the VD) although the protein persists through to E14.5. By E16.5, Otx2/Otx2 is absent from either RP or the VD. Homozygous-null mutant mice, which die midgestation, exhibit severe malformations of the forebrain structures as well as the eyes due to impaired gastrulation. Heterozygous mice present with variable eye phenotypes ranging from normal to severe (anophthalmia/microphthalmia) and brain structural abnormalities (holoprosencephaly or anencephaly). Its potential role in pituitary development was suggested in a recent report looking at Prop1-mutant mice [18] . In these animals, Otx2 expression in RP persists through to E16.5, which is 4 days after peak expression of Prop1 and 2 days later than any obvious pituitary morphology defects become apparent. This suggested that Prop1 may regulate genetic expression of factors which may suppress Otx2 expression and implies a role for Otx2 in murine pituitary development. Further evidence of a role in hypothalamo-pituitary development was shown in GnRH-neuron-Otx2 knockout mice which exhibited hypogonadotrophic hypogonadism [19] . These data are consistent with human OTX2 phenotypes which can encompass highly variable hypopituitary phenotypes (ranging from isolated growth hormone deficiency to panhypopituitarism) and hypogonadotrophic hypogonadism, both of which are most commonly detected in association with severe eye abnormalities including anophthalmia or microphthalmia. To date, OTX2 mutations, of which 20 have been described, account for 2-3% of severe eye abnormalities (table 1) [3] .
Factors Regulating Cellular Differentiation PROP1 and POU1F1/PIT1 Prop1 is a transcriptional activator whose primary role is to stimulate pituitarycell differentiation. At E9.0, its expression is repressed by Hesx1. Subsequently, it is expressed in Rathke's pouch, and believed to form heterodimers with Hesx1. By E12.5, levels of Prop1 are believed to be sufficient to displace Hesx1 such that homodimers are formed. At this point, Prop1 stimulates the differentiation and proliferation of each of the hormone-secreting cell lineages. Mutations in PROP1 are associated with GH, prolactin and TSH deficiencies, but in addition also manifest gonadotrophin and ACTH deficiencies which may be present at a young age, or may evolve with time. MRI reveals either a small or enlarged anterior pituitary that may wax and wane in size before eventual involution (table 1) [4, 20] . The posterior pituitary is structurally normal. Mutations in PROP1 have in several studies been described as the most prevalent cause of combined pituitary hormone deficiency (CPHD) in humans, accounting for up to 50% of familial cases of CPHD. However, the prevalence of mutations is much lower in sporadic cases.
While the exact mechanisms of how Prop1 drives gonadotroph and corticotroph differentiation remain unclear, the stimulation of somatotroph, lactotroph and thyrotroph differentiation is driven via the activation of the POU domain, class 1, transcription factor (Pou1F1, also known as Pit1) at E13.5 [21] . Consequently, mutations in POU1F1 are associated with GH, prolactin and TSH deficiencies in the presence of a normal or small anterior pituitary gland on MRI, with a structurally normal posterior pituitary (table 1) . Another transcription factor, PITX1, is thought to synergise with POU1F1 to augment prolactin gene expression and, to a lesser extent, growth hormone gene expression [4] . In gonadotrophs it activates Lhb expression. Mutations in this gene have not been implicated in hypopituitarism in humans, however. GATA2 GATA2 belongs to a family of six transcription factors. It has dual functions; (1) as a stem cell maintenance factor in some tissues, and (2) as a promoter of cellular differentiation in others [22] . Following induction by BMP2 at E10.5, Gata2 is expressed in the ventral RP along with α-GSU, the common subunit of Lh, Fsh, and Tsh. It therefore marks the prospective, and then definitive, gonadotrophs and thyrotrophs; its expression is maintained in the adult. Gata2 can synergise with Pou1f1 to induce Tshβ expression and synergise with Nr5a1 to increase Lhb gene expression [4] . Despite its known role in regulating the human α-GSU gene, no mutations have been described in humans in association with hypopituitarism. TBX19 TBX19 (previously referred to as TPIT) is a member of the T-Box family of transcription factors. Tbx19 is exclusively expressed in the developing pituitary, first at E12.5 in Pomc-positive cells, then in corticotrophs and melanotrophs, where it is maintained in the adult gland [23] . Pomc transcription requires cooperation between Tbx19 and Pitx1, the two factors binding to contiguous sites within the same regulatory element. The essential role of Tbx19 for differentiation of pituitary Pomc lineages was ascertained in Tbx19 null mutant mice which exhibit an almost complete loss of pituitary Pomc-expressing cells [4] , resulting in severe Acth and glucocorticoid deficiencies. There is a mutual antagonism between Tbx19 and Nr5a1, the latter being important for gonadotroph development. Therefore, Tbx19 promotes and is required for corticotroph and melanotroph fate determination while actively repressing gonadotroph differentiation. Mutations in TBX19 are the commonest cause of isolated ACTH deficiency presenting with life-threatening hypoglycaemia in the neonatal period in humans (table 1) .
Congenital Hypopituitarism and Associated Defects
As mentioned earlier, the pituitary gland is a midline structure and so defects affecting the development of this organ may impact on the development of associated structures, which can lead to highly heterogeneous phenotypes including HPE and SOD. Genetic mutations have been implicated in these disorders but in a very low proportion of cases (approximately 5-10% of patients studied) thereby indicating that many more causative genes or other aetiological factors remain to be uncovered.
HPE is the most common forebrain anomaly in humans, occurring at an incidence of 1:10,000-20,000 in the general population and as high as 1:250 in conceptuses [3] . It is caused by varying degrees of separation of the cerebral hemispheres and ventricles [3] . Failure of the frontal and parietal lobes to divide posteriorly result in the loss of the corpus callosum ( fig. 3) . Facial features associated with the disorder include cyclopia, anophthalmia, midface hypoplasia, hypotelorism, cleft lip and/or palate and a single central incisor. An increasing number of genetic factors and associated pathways have been implicated in the aetiology of HPE and include members of the Sonic Hedgehog pathway including SHH, ZIC2, TGIF1, PTCH1, GLI2, DISP1, TDGF1, GAS1, EYA4 and FOXH1 [10] . More recently, the first case of autosomal recessive HPE was assigned to a mutation in FGF8 [10] .
Septo-optic dysplasia (SOD) is diagnosed when any two of the following phenotypes are present: (1) optic nerve hypoplasia, (2) midline neuroradiological abnormalities such as agenesis of the corpus callosum and septum pellucidum, and (3) anterior pituitary hypoplasia with consequent hypopituitarism [3] . While generally sporadic and inclusive of possible environmental induced pathologies through smoking and drug/alcohol abuse, there is an increasing number of implicated genetic mutations involving HESX1, OTX2, SOX2 and SOX3 (table 1). As mentioned earlier, these genes, and those implicated in HPE, are expressed early in forebrain and pituitary development and, as such, mutations within may be expected to induce congenital hypopituitarism and associated phenotypes.
Overlap between Congenital Hypopituitarism and Midline Defects with Kallmann Syndrome
Recent evidence has suggested a possible overlap between Kallmann syndrome and midline disorders that include hypopituitarism. A number of phenotypic features are shared by the two disorders including craniofacial defects (high-arched palate, cleft lip/palate) [3] , dental agenesis and sensorineural hearing loss. A number of genes have been implicated in the aetiology of Kallmann syndrome, including KAL1, FGFR1, FGF8, PROKR2 and PROK2 with recent additions including the chromodomain helicase DNA binding protein-7 (CHD7), Bromodomain and WD repeat-containing protein 2 (WDR11), negative elongation factor (NELF) and Semaphorin 3A (SEMA3A) [24] [25] [26] .
The original Kallmann syndrome associated genes are involved in the maturation and/or migration of gonadotrophin-releasing hormone neurons from the olfactory placode to the hypothalamus. These genes are also involved in the maturation of the olfactory complex itself, hence the anosmic phenotype characteristic of the condition. Recently, mutations in FGFR1 and FGF8 have been implicated in CPHD, SOD and HPE highlighting an overlap in genotypes between these conditions and consistent with the overlap in phenotypes [10, 24] . Furthermore, PROKR2 sequence variants that had previously been implicated in the aetiology of KS have also been recently identified in patients with congenital hypopituitarism and SOD [24] . Thus, as previously observed with HESX1, sequence variants may be associated with variably penetrant phenotypes. This is suggestive of a possible digenic or oligogenic cause of congenital hypopituitarism; a phenomenon which is now well established in the aetiology of KS [24] . Thus, the molecular basis of these disorders is complex and could involve defects in multiple factors, as well as possible interactions with the environment.
Current data suggest that the aetiological basis of congenital hypopituitarism is far from straightforward; given that only between 5 and 15% of cases have an associated genetic variant. The advent of homozygosity mapping and whole exome sequencing however opens new avenues for the identification of novel genes implicated in congenital hypopituitarism and associated disorders.
Conclusions
The development of the pituitary is a highly complex and organised process involving spatio-temporally arranged signalling molecules and transcription factors. This chapter has provided an overview of pituitary development and some of the molecules involved in the process. Mutations in the genes encoding these molecules can lead to congenital hypopituitarism, including disorders such as HPE and SOD. Such genetic anomalies only account for a small percentage of cases although the apparent overlap in genotypes with Kallmann syndrome opens a new, albeit limited, source of potential genetic associations. It is expected that with the advent of homozygosity mapping and whole exome sequencing, new genes will be implicated in both of these groups of disorders thereby enhancing our understanding of pituitary development and how defects in these newly identified genes may impact on human phenotypes.
